The pharmacological characterization of the major metabolite of infigratinib clarifies clinically-observed side-effects and unlocks repurposing opportunities

• Luca Ruvo ^[1] ; Leticia Manen-Freixa ^[1] ; S. Santos ^[1]
  1. [1] This overlooked dimension of pharmacology could open new avenues for drug repurposing and more effective patient treatment
• Localización: Actualidad en farmacología y terapéutica, ISSN 1698-4277, Vol. 23, Nº. 4, 2025, págs. 306-308
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Drug metabolites are often present in the plasma of patients at significant concentrations, yet they remain largely uncharacterized in drug discovery and development. A few recent studies demonstrate that drug biotransformation can yield chemical entities with distinct potency, selectivity and safety profiles relative to their parent drugs, and that such metabolites can materially contribute to efficacy and adverse effects when systemic concentrations are appreciable.